FilingsTodaySteris
At a glance
Steris reported 2025 revenue of $5.94B, up 8.7% from $5.46B in 2024. Over 4 years since 2021 ($4.22B), that is growth of about 8.9% a year. Operating margin was 18.6%, up from 11.3% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 7 insiders reported 0 open-market purchases and 8 sales ($9.8M). 2 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $4M by Sr. VP, Gen Counsel, and Sec. John Adam Zangerle on Nov 13, 2025.
Steris filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (3), material agreement (1) and shareholder vote results (1). The latest officer or director change was reported on Aug 6, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
3 of the 20 investors tracked here held Steris at the last quarter end, worth $32.8M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Renaissance Technologies. Reduced: Bridgewater Associates and National Pension Service (Korea).
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $243.9M | $107M | $378.2M | $614.6M | $782.3M |
| Diluted EPS | $2.48 | $1.07 | $3.81 | $6.20 | $7.93 |
| Dividend per share | $1.69 | $1.84 | $2.03 | $2.23 | $2.46 |
Fiscal year ends Mar 31 · incorporated in L2
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined